吉西他滨联合多烯紫杉醇治疗晚期肺腺鳞癌的临床效果评价
[摘要]目的 探讨吉西他滨联合多烯紫杉醇治疗晚期肺腺鳞癌的临床效果。方法 选取2013年10月～2017年1月我院收治的92例晚期肺腺鳞癌患者作为研究对象，采用随机数字表法将其分为观察组和对照组，每组各46例。对照组患者给予多烯紫杉醇治疗，观察组患者在此基础上给予吉西他滨进行联合治疗。比较两组患者的治疗效果、平均生存时间（OS）及不良反应发生情况。结果 观察组患者的治疗总有效率（91.30%）高于对照组（78.26%），差异有统计学意义（P<0.05）。观察组患者的平均OS为（25.59±4.59）个月，对照组患者的平均OS为（13.49±2.91）个月，观察组患者的平均OS长于对照组，差异有统计学意义（P<0.05）。两组患者的不良反应发生情况比较，差异无统计学意义（P>0.05）。结论 吉西他滨联合多烯紫杉醇治疗晚期肺腺鳞癌的临床效果显著，可明显提高患者的生存时间，具有较高的临床应用价值，值得推广。
[关键词]吉西他滨；多烯紫杉醇；晚期肺腺鳞癌；临床效果
[中图分类号] R814.42 [文献标识码] A [文章编号] 1674-4721（2018）2（b）-0138-03
The clinical effect of Gemcitabine combined with Dolitaxel in treatment of advanced lung adenoid squamous carcinoma
AN Shi-xing
Department of Oncology，the First Hospital in Laohekou City，Hubei Province，Laohekou 441800，China
[Abstract]Objective To explore the clinical effect of Gemcitabine combined with Dolitaxel in the treatment of advanced lung adenoid squamous carcinoma.Methods 92 patients with advanced lung adenocarcinoma treated in our hospital from October 2013 to January 2017 were selected as the study subjects，and were randomly divided into observation group and control group according to the random number table method，46 cases in each group.The patients in the control group were treated with Docetaxel，and the patients in the observation group were given Gemcitabine for combined treatment on this basis.The treatment effect，average survival time （OS） and adverse reactions were compared between the two groups.Results The treatment of total effective rate of patients in the observation group （91.30%） was lower than that in the control group （78.26%），and the difference was statistically significant （P<0.05）.In observation group，the average OS was （25.59±4.59） months，while the average OS in the control group was （13.49±2.91） months，the average OS in the observation was longer than that in the control group，and the difference was statistically significant （P<0.05）.There was no statistically significant difference in adverse reactions between the two groups （P>0.05）.Conclusion The clinical effect of Gemcitabine combined with Dolitaxel in the treatment of advanced lung adenoid squamous cell carcinoma is significant，which can obviously improve the survival time of patients and has high clinical application value and is worth promoting.
[Key words]Gisidhambin；Dolitaxel；Advanced lung adenoid squamous carcinoma；Clinical effect
肺腺鱗癌（ASC）是极其少见的一种癌症，其患病率只有肺癌的0.6%～2.3%。临床诊断肺部肿瘤中含有10%以上的腺癌或鳞癌成分才可判定为肺腺鳞癌，常位于外周并伴有中央瘢痕形成[1-3]。晚期ASC的生存概率是非常渺茫的，通常临床应用化疗的方式来延缓患者的寿命。ASC属于非小细胞肺癌的一种，化疗对不同组织类型非小细胞肺癌所产生的效果也不同[4]，本研究选取我院收治的92例晚期ASC患者作为研究对象，探讨吉西他滨联合多烯紫杉醇治疗晚期ASC的临床疗效，现报道如下。